Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Abstract

15 patients receiving cytotoxic drugs (other than cisplatin) that had previously produced nausea and vomiting refractory to first-line antiemetics were given a selective 5-HT3 receptor antagonist (GR38032F), 4 mg intravenously and 4 mg orally, immediately before chemotherapy, the oral dose being repeated 5 and 10 h later. Nausea, vomiting, and side-effects… (More)

Topics

Cite this paper

@article{Cunningham1987PreventionOE, title={Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.}, author={David C. Cunningham and J. Bland - Hawthorn and Andrew K Pople and J C Gazet and Hubert T. Ford and Teresa Challoner and R C Coombes}, journal={Lancet}, year={1987}, volume={1 8548}, pages={1461-3} }